Management of Hepatic Encephalopathy in Patients with Decompensated Cirrhosis

Learner Site

<< Back

0 Item(s)

Keyword(s) Gastro, Bites, Bite, GastroBite, Gastro-Bites

Nov. 4, 2025 — Noon-1 p.m. EDT

Tag(s) Live meetings/webinars, Liver, Hepatic encephalopathy

Description

Tuesday, Nov. 4, 2025

12–1 p.m. EDT  

Join us for this upcoming event in our Gastro Bites series — virtual webinars with leading experts.

Hepatic encephalopathy (HE) is an urgent clinical reality and a leading cause of hospitalization in patients with cirrhosis. This session will review the diagnosis and management of HE in patients with cirrhosis, addressing both acute treatment and strategies for secondary prevention.

Learning objectives:

Differentiate compensated vs. decompensated cirrhosis.
Understand complications of decompensated cirrhosis, with a focus on HE.
Describe the pathophysiology of HE, the diagnosis of HE, and the differentiation of the HE grades.
Provide proper management strategies for the management of a patient with overt HE acutely and long-term (secondary prophylaxis).

Speakers:

Kimberly Brown, MD
Chief of the Division of Gastroenterology and Hepatology
Associate Medical Director of Henry Ford Hospital Transplant

Arun Jesudian, MD
Associate Professor of Clinical Medicine
Director of Liver Quality and Inpatient Liver Services
New York-Presbyterian Hospital/Weill Cornell

Apurva Modi, MD, MS, MHSc
Transplant Hepatology
Baylor Scott & White

Pricing:

Member	Nonmember
Free	Free

Sponsor:

This session is sponsored by Salix Pharmaceuticals, Inc.

Accreditation Statement 

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The AGA Institute designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose all their financial relationships with ineligible companies held within the past 24 months. The AGA Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners. 

CME expiration date: Aug. 25, 2026 

Disclosures:

Kelly Issokson, MS, RD, LDN, serving as course director, and speaker for this educational activity, disclosed the following relevant financial relationships:

Consultant: Takeda and Ironwood 
Speaker: Ajinomoto-Cambrooke

Eric Vasiliauskas, MD, serving as course director, and speaker for this educational activity, has no relevant financial relationships with ineligible companies to disclose. 

Madison Simons, PsyD, serving as a speaker for this educational activity, has no relevant financial relationships with ineligible companies to disclose. 

All relevant financial relationships have been mitigated. 

Resources

Missing the Mark: Hepatic Encephalopathy